Jessica Vega spent years trying to quit drinking before a GLP-1 medication did what other treatments could not: it made her alcohol cravings disappear. Martha Stewart is facing pointed criticism for promoting a GLP-1 drug she says she does not take herself, and Chrissy Metz is pushing back against critics of her own weight loss. For the roughly 40 million Americans now on these medications, questions about who profits from them and who might lose coverage for them are no longer abstract.
Vega had struggled with alcohol addiction for years, trying various treatments that did not stop her cravings. She says her drinking urges disappeared after she started a GLP-1 medication, a shift that came after everything else had failed. Her experience adds to a growing body of anecdotal reports linking these drugs to reduced interest in alcohol, not just food. For someone who had tried other paths without success, this outcome came as an unexpected relief. It also raises questions about how many other people might be experiencing something similar without recognizing why.
While Vega credits her medication with changing her relationship to alcohol, Martha Stewart is facing a different kind of scrutiny over her own relationship to a GLP-1 drug. Stewart has been advertising a GLP-1 medication publicly while stating that she does not personally take it. Critics have questioned whether that arrangement is honest, given that her endorsement could shape how consumers think about the drug's use and effectiveness. The core question is straightforward: can someone credibly promote a treatment they admit they don't use themselves? The controversy is a reminder that celebrity endorsements carry real weight for a drug category already crowded with public figures weighing in.
Chrissy Metz is dealing with a related but different kind of public reaction. She has faced criticism over her own GLP-1 weight loss, with some questioning her choice to use the medication at all. Metz has pushed back directly, defending her decision as a personal one made for her own health. Her response echoes a pattern seen with other public figures who have chosen to speak openly about their GLP-1 use rather than stay silent under criticism. The willingness to defend that choice publicly stands in contrast to Stewart's more complicated position of endorsing a drug she says she avoids.
There is a more practical concern behind these public debates: insurance coverage. Losing access to GLP-1 coverage through a health plan can add hundreds of dollars to a patient's monthly costs. That gap between plans that cover the medications and those that don't is becoming a bigger factor in whether patients can continue treatment at all. For patients who have found real benefit, whether for weight loss or diabetes management, that gap can mean the difference between staying on a medication and dropping it. The stakes are higher for someone like Vega, whose benefit went beyond the reasons insurers typically recognize when they decide what to cover.
All of this touches a much larger group than the individuals named above. About 40 million Americans currently use GLP-1 medications, a number that reflects how mainstream these drugs have become. Despite that scale, common misconceptions persist about what the medications do and who takes them, misconceptions that shape everything from insurance policy decisions to public reactions toward people like Metz. Vega's experience with alcohol cravings is itself a sign of how incomplete the public understanding of these drugs still is. As more people use GLP-1 medications for a widening range of reasons, the gap between what patients experience and what the public assumes is likely to keep drawing attention.
For readers considering a GLP-1 medication or already taking one, the takeaway is to pay attention to your own experience rather than relying on assumptions from headlines or celebrity endorsements. If you notice unexpected changes, such as reduced interest in alcohol, it may be worth discussing with your doctor rather than dismissing it as unrelated. It is also worth checking your insurance plan's coverage terms now, before any changes take effect, so you are not caught off guard by a sudden increase in cost. Staying informed about both the personal and financial sides of these medications will serve you better than following any single narrative about them.
Key details
Jessica Vega says a GLP-1 helped her stop drinking after years of addiction.
Martha Stewart faces criticism for advertising a GLP-1 drug she says she doesn't use.
Chrissy Metz has defended her GLP-1 weight loss experience against public criticism.
Losing GLP-1 coverage could cost patients hundreds of dollars more each month.
About 40 million Americans currently use GLP-1 medications despite common misconceptions.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.